Elegant
Mevion has designed a high energy proton source –
the world’s first superconducting synchrocyclotron – that dramatically reduces
the size, cost, and complexity of proton acceleration. Powered by a
gantry-mounted TriNiobium Core™, the MEVION S250 has a footprint only slightly
larger than a conventional linac, yet delivers the incredible targeting
advantages of proton therapy with higher throughput. The result is a truly
elegant cancer care solution, as economical as it is precise.
Precise
Optimal dose
distribution – the ultimate goal of radiation therapy devices and practice – is
the intrinsic value of proton therapy. The MEVION S250 delivers on the
therapeutic promise of high energy particle radiation by mounting the
TriNiobium Core on the industry’s first concentric gantry, resulting in higher
isocentric accuracy. When combined with full robotic positioning,
multidimensional imaging, and Mevion’s fourth-generation DirectDose™ beam
modulating system, a level of radiation-targeting precision is achieved that is
not possible with traditional devices.
The MEVION S250 Proton Therapy System is USFDA 510(k) cleared and complies with MDD/CE requirements

